MINNEAPOLIS, March 16, 2016 -- MOCON, Inc. (Nasdaq:MOCO) announced today that Robert L. Demorest, President and Chief Executive Officer, and Elissa Lindsoe, Chief Financial Officer, will be presenting on behalf of MOCON at the 2016 Sidoti Emerging Growth Convention to be held in the Broadway Ballroom of the Marriott Marquis in New York, NY on Thursday, March 31st, 2016.
| Event: | Sidoti Emerging Growth Convention |
| When: | Thursday, March 31, 2016 |
| Where: | New York Marriott Marquis – 6th Floor |
| 1535 Broadway, New York, NY 10036 (45th & Broadway) |
MOCON is scheduled to deliver a presentation from 2:00 - 2:30 pm EDT followed by a Q&A with the audience. Admission is open to both institutional and retail investors.
To schedule a one-on-one meeting with management, please contact John DeBono at [email protected] or 212-894-3313.
Those interested in attending the event should call 212-453-7031 or email [email protected] to register.
About the Sidoti Emerging Growth Convention
The 2016 Sidoti Emerging Growth Convention is a unique forum where management teams of companies with a market cap of $1 billion or less connect with small and micro-cap institutional investors, research analysts, investment bankers, private equity professionals and select media with the goal of expanding institutional awareness amongst key stakeholders in the investment community. The 2016 Emerging Growth Conference will be held on March 31, 2016 at the Marriott Marquis in Times Square, New York. The event is one of the leading small and micro-cap investment conferences of the year featuring presentations by more than 80 public companies, with past attendance exceeding 400 investors.
About Sidoti & Company, LLC
A leading provider of institutional-quality equity research focused on small, publicly-traded companies that meet our proprietary criteria, Sidoti’s research coverage universe comprises nearly 300 companies across a range of industries. These companies typically have market capitalizations of less than $3 billion and a history of profitability, and generally maintain strong balance sheets. Our approach affords institutional investor clients a combination of high-quality research; a small- and micro-cap company focused nationwide sales effort; broad access to corporate management teams and extensive trading support.
About MOCON
MOCON is a leading provider of detectors, instruments, systems and consulting services to research laboratories, production facilities, and quality control and safety departments in the medical, pharmaceutical, food and beverage, packaging, environmental, oil and gas and other industries worldwide. See www.mocon.com for more information.
MOCON, Inc. Investor Contact: Elissa Lindsoe, 763-493-6370 CFO www.mocon.com or Three Part Advisors, LLC Steven Hooser, 214-872-2710 Investor Relations [email protected]


Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 



